- Home
- TPST vs IOBT Comparison
TPST vs IOBT Comparison
Compare TPST & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- IOBT
- Stock Information
- Founded
- TPST 2011
- IOBT 2014
- Country
- TPST United States
- IOBT Denmark
- Employees
- TPST N/A
- IOBT N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- TPST Health Care
- IOBT Health Care
- Exchange
- TPST Nasdaq
- IOBT Nasdaq
- Market Cap
- TPST 45.5M
- IOBT 50.5M
- IPO Year
- TPST N/A
- IOBT 2021
- Fundamental
- Price
- TPST $10.45
- IOBT $0.99
- Analyst Decision
- TPST Hold
- IOBT Buy
- Analyst Count
- TPST 3
- IOBT 4
- Target Price
- TPST $30.00
- IOBT $3.50
- AVG Volume (30 Days)
- TPST 47.7K
- IOBT 9.5M
- Earning Date
- TPST 11-11-2025
- IOBT 11-11-2025
- Dividend Yield
- TPST N/A
- IOBT N/A
- EPS Growth
- TPST N/A
- IOBT N/A
- EPS
- TPST N/A
- IOBT N/A
- Revenue
- TPST N/A
- IOBT N/A
- Revenue This Year
- TPST N/A
- IOBT N/A
- Revenue Next Year
- TPST N/A
- IOBT N/A
- P/E Ratio
- TPST N/A
- IOBT N/A
- Revenue Growth
- TPST N/A
- IOBT N/A
- 52 Week Low
- TPST $5.35
- IOBT $0.32
- 52 Week High
- TPST $15.73
- IOBT $2.79
- Technical
- Relative Strength Index (RSI)
- TPST 49.98
- IOBT 50.67
- Support Level
- TPST $10.09
- IOBT $0.62
- Resistance Level
- TPST $10.79
- IOBT $1.23
- Average True Range (ATR)
- TPST 0.68
- IOBT 0.13
- MACD
- TPST -0.11
- IOBT 0.09
- Stochastic Oscillator
- TPST 16.93
- IOBT 66.12
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.